Key traits needed by leaders looking to grow their organizations in the biosimilars market.
Increase in new treatments also brings increase in logistical challenges for pharma.
Delivering better patient outcomes hinges on innovation and adaptability.
Investments setting up sector for future success that could one day rival its US counterpart.
Faster launch planning leads to greater access.
Cybersecurity vulnerabilities embedded in AI and machine learning pose significant litigation risks as life sciences companies move to digital technologies.
There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.
The current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
KOLs in the sector examine the current dealmaking landscape, including the status of available capital.
While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.
Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.
Three ways artificial intelligence can drive the necessary engagement between patients and HCPs.
Outlining the implications of this c-suite trend for pharma.
Addressing the increased use of technology in safety compliance processes and greater patient involvement.
While patient support providers play an important role in keeping patients on therapy, biopharma companies have a great opportunity to push analytical sophistication beyond what many of these providers currently offer.
Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.
Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?
The emergence of organized customers demands investment in advanced solutions and next-generation key account management.
A deep-dive into how pharma companies can apply service operations principles to achieve a greater level of marketing and promotional review committee satisfaction.
A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.
The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.
Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.
Companies must determine the right ways to utilize AI.